Apheresis Market Size

Global Apheresis Market Overview

Apheresis Market Size was valued at USD 1.14 Billion in 2023. The Apheresis industry is projected to grow from USD 1.20 Billion in 2024 to USD 2.10 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.00% during the forecast period (2024 - 2032). Favorable government initiatives and the rising prevalence of blood-related disorders are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

December 2023 saw TERUMO BCT, INC. participate in the second Connecting the Dot series, which was a film series created specifically for European MedTech companies.

FDA approved BioLineRx Ltd.’s APHEXDA (motixafortide) with filgrastim as a means of mobilizing hematopoietic stem cells in multiple myeloma patients back in September 2023. Stem cell collection relies on apheresis machines that enable separation of blood components desired from donors or patients during procedures like leukapheresis and HPC collection for various medical treatments.

August 2023, there was clearance by the US FDA on a Terumo BCT, Inc. platelet device that processes blood into platelets using a single centrifugation cyclex.

For example, in August 2023, Fresenius Kabi AG entered into a supply and development agreement with Lupagen Inc. to develop technologies for bringing cell and gene therapies closer to patients’ bedside. This action reflects the industry’s strategic moves towards strengthening market positions and driving innovation.

In May 2023, TERUMO BCT, INC. initiated the first training program aimed at helping manufacturers of cell and gene therapy improve their methods of collecting cells, leading to the commercialization of therapeutic products.

Apheresis Market Trends

• Growing prevalence of various diseases to boost market growth

The prevalence of chronic conditions like cancer and autoimmune diseases is expected to increase, accelerating market expansion. According to the National Stem Cell Foundation (NSCF), over 80 different autoimmune diseases affect about 4% of the world's population. In the United States, autoimmune diseases are the third most common cause of chronic illness. According to Johns Hopkins Medicine Pathology, 3%, or about 10 million people, of the population of the United States are affected by all autoimmune diseases. TPE, or therapeutic plasma exchange, is frequently used to treat autoimmune diseases.

The market is anticipated to benefit from the increase in platelet donors and R&D expenditures by biopharmaceutical companies. Around one in every 5,000 male births is affected by hemophilia A, according to the Centers for Disease Control and Prevention. Every year, 400 infants are born with hemophilia. The demand for apheresis equipment is rising due to the rising complexity of surgical procedures and the rising demand for various blood components. The American National Red Cross estimates that the United States needs about 29,000 units of RBCs every day. Every year, roughly 16 million blood components are transfused. Therefore, growing blood donation and a rising number of blood banks fuel the Apheresis market CAGR.

Figure 1 Number of Blood Banks in India

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

WHO advises that all blood collection, testing, processing, storage, and distribution activities be coordinated nationally using efficient administration and cohesive blood supply networks. National blood policy and legislative framework should govern the nation's blood system to encourage the uniform application of standards and consistency in the quality and safety of blood and blood products. 125 of the 171 countries reported in 2018 had a national blood policy of 73%. Overall, 113 out of the 171 reporting countries, or 66%, have laws that specifically address the security and caliber of blood transfusions. Worldwide, blood donations total about 118.54 million. 16% of the world's population lives in high-income countries, where 40% of these are collected. Growing initiatives by the government are another factor driving the growth of the Apheresis market revenue.

Apheresis Market Segment Insights

Apheresis Product Insights

Based on products, the market segments of Apheresis includes Devices and Disposables. The Disposables segment held the majority share in 2022, contributing to around ~65-67% of the market revenue of Apheresis. Numerous improvements in the production of blood bags, disposable kits, and tubing are some elements contributing to the market expansion. The segment's growth is driven by increased demand for automated component separation processes, particularly in developed markets.

May 2019 Macopharma has just released its cord blood collection bag with two needles that has received FDA and NDA approval in the US. For more than 15 years, Macopharma has been a top provider of cord blood collection kits in Europe and the rest of the world.

Figure 2 Apheresis Market, by Products, 2023 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Apheresis Procedure Insights

Based on procedure, the  Apheresis market segmentation includes plateletpheresis, leukapheresis, erythrocyte apheresis, and plasmapheresis. The plateletpheresis segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Patients with compromised immune systems receive plasma-based medications to increase their resistance to infection and disease. The market is anticipated to expand as the prevalence of blood-related diseases increases and the demand for therapies derived from plasma rises. White blood cells (WBC) are removed from the blood drawn from the body using plasmapheresis. The demand for plasmapheresis is anticipated to increase due to the necessity of this type of surgery to treat graft-versus-host disease (GvHD) and T-cell lymphoma (CTCL). Hence, such factors are positively impacting the market growth.

Apheresis Method Insights

The Apheresis market data has been bifurcated by method into Centrifugation and Filtration. The Centrifugation segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Compared to membrane filtration, centrifugation produces results more quickly, easily, and precisely, which explains why it is more frequently used. Additionally, the segment is anticipated to grow in response to the rising demand for automated apheresis systems. To increase the effectiveness of their products, businesses are developing sophisticated, automated technology. The producers create continuous flow centrifugation, an automated interface system, and a customized anticoagulant infusion system for automatic apheresis equipment.

Apheresis Application Insights

Based on Application, the Apheresis industry has been segmented into oncological, renal, cardiovascular, hematological, neurological, and immunological diseases. Neurological diseases held the largest segment share in 2022. The dominant share of the market is attributed to the critical need for therapeutic apheresis in the management of highly prevalent neurological disorders like multiple sclerosis and autoimmune neurological disorder.

Apheresis End User Insights

Based on End Users, the Apheresis industry has been segmented into Blood Banks and Hospitals. Blood banks held the largest segment share in 2022, owing to the growing number of blood banks and rising blood donations ly. The demand for apheresis is rising due to the increasing need for various blood components and the complexity of surgical procedures.

Apheresis Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America Apheresis market accounted for USD 0.5 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The main drivers of the market in North America are the rising prevalence of blood-related diseases like kidney disease, metabolic disease, cancer, and neurological disorders, the rising number of donors, and the demand for blood components. The American National Red Cross estimates that nearly 6.8 million Americans donate blood annually.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 APHERESIS MARKET SHARE BY REGION 2023 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Apheresis market accounts for the second-largest market share in 2022. The market growth is anticipated to be fueled by the rising prevalence of blood-related disorders, the availability of supportive government initiatives, and reimbursement frameworks. Further, the Germany market of Apheresis held the largest market share, and the UK market of Apheresis was the fastest-growing market in the European region

The Asia-Pacific Apheresis Market is expected to grow at the fastest CAGR from 2024 to 2032. One of the major factors contributing to this increase in revenue share is the rising prevalence of blood disorders necessitating plasma and platelet transfusions in developing nations like China and India. Additionally, during the forecast period, the industry is anticipated to benefit from an improved growth environment due to the region's expanding healthcare practitioner population and improved healthcare infrastructure. Moreover, China market of Apheresis held the largest market share, and the India market of Apheresis was the fastest-growing market in the Asia-Pacific region

Apheresis Key Market Players & Competitive Insights

Major market players are investing in the R&D of various products that are advanced and low-cost. Market participants frequently use inorganic strategic alliances, such as partnerships, acquisitions, and capacity expansions, in addition to investments, to strengthen their market positions and gain competitive advantages. Competitors in the Apheresis industry must offer cost-effective items to survive in an increasingly competitive environment.

One of the key strategies manufacturers adopt in the Apheresis industry is launching new products in the market. In recent years, the Apheresis industry has been collaborating with other companies in the market. The Apheresis market major player such as Asahi Kasei Medical Co. Ltd. (Japan), Fresenius Medical Care (Germany), Terumo BCT Inc. (US), Haemonetics Corporation (US), Kawasumi Laboratories Inc. (Japan), HemaCare Corporation (US), Kaneka Corporation (Japan), Nikkiso Co.Ltd. (Japan), and others are working on expanding the market demand by investing in research and development activities.

Terumo BCT is a leader in cell therapy, therapeutic apheresis, blood management, blood safety, and cell collection. In July 2022, Eliaz Therapeutics and Terumo Blood and Cell Technologies worked to create and market a novel therapeutic apheresis therapy for acute kidney injury. (AKI).

Fresenius Medical Care is a company whose innovative therapies, services, and products are building a future worth living with acute and chronic kidney dialysis and therapeutic apheresis. In March 2022, Fresenius Medical Care North America, Fresenius Health Partners, InterWell Health, the leading physician organization driving innovation in the kidney care sector in the U.S., and Cricket Health, a U.S. provider of value-based kidney care with a premier patient engagement and data platform, have entered into a legally binding agreement to form an independent new company.

Key Companies in the market of Apheresis include

• Asahi Kasei Medical Co. Ltd. (Japan)


• Fresenius Medical Care (Germany)


• Terumo BCT Inc. (US)


• Haemonetics Corporation (US)


• Kawasumi Laboratories Inc. (Japan)


• HemaCare Corporation (US)


• Kaneka Corporation (Japan)


• Nikkiso Co.Ltd. (Japan), among others

Apheresis Industry Developments

January 2020 Fresenius Kabi, for €30 million, expanded its Dominican Republic's transfusion and apheresis disposables plant.

June 2022 Terumo Blood and Cell Technologies announced that NHS England in the UK had chosen the automated red blood cell exchange (RBCX) procedure on the company's Spectra Optia® Apheresis System through the NHS MedTech Funding Mandate (MTFM).

Apheresis Market Segmentation

Apheresis Product Outlook

• Devices


• Disposables

Apheresis Procedure Outlook

• Plateletpheresis


• Leukapheresis


• Erythrocytapheresis


• Plasmapheresis

Apheresis Methods Outlook

• Centrifugation


• Filtration

Apheresis Application Outlook

• Oncological Diseases


• Renal Diseases


• Cardiovascular Diseases


• Hematological Diseases


• Neurological Diseases


• Immunological Diseases

Apheresis End User Outlook

• Blood Banks


• Hospitals

Apheresis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America